SBTX Silverback Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.

$6.86  +0.08 (1.18%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/03/2020
Outstanding shares:  35,076,083
Average volume:  366,442
Market cap:   $237,815,843
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    82835W108
ISIN:        US82835W1080
Sedol:      BMCR7V2
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.72
PS ratio:   0.00
Return on equity:   -23.82%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy